Abstract
In the present study we used the nicotinic ligand 5-iodo-A-85380 [5-iodo-3(2(S)-azetidinylmethoxy)pyridine], which selectively binds to β2-containing nicotinic acetylcholine receptors, to elucidate the nicotinic receptor subtypes affected by nigrostriatal damage in the monkey. Autoradiographic studies in control monkeys showed that 5-[125I]A-85380 ([125I]A-85380) binds throughout the brain with the characteristics of a nicotinic receptor ligand. Competition experiments with cytisine and nicotine yielded Ki values of ∼1 and 10 nM, respectively, with complete inhibition of [125I]A-85380 binding at a 10−6 M concentration of these ligands. In contrast, α-conotoxin MII blocked radioligand binding in the striatum by 30% at the highest concentrations, suggesting that a subset of striatal [125I]A-85380 sites are α-conotoxin MII-sensitive. Monkeys treated with the nigrostriatal neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine showed a selective decrease in striatal [125I]A-85380 sites, with a 42% reduction in the caudate and putamen of animals with moderate nigrostriatal lesioning and a 53% decline in the striatum of severely lesioned animals. Our previous work had demonstrated that there were two populations of nicotinic receptors eliminated after nigrostriatal damage, an α-conotoxin MII-sensitive and an α-conotoxin MII- resistant subtype. Analysis of both striatal [125I]A-85380 and [125I]epibatidine competition studies extend our earlier studies by demonstrating that the α-conotoxin MII-sensitive sites eliminated after moderate nigrostriatal lesioning appear to be composed of two nicotinic receptor subtypes. The data may be important for potential therapeutic approaches because they suggest that there are at least three populations of nicotinic receptors in monkey striatum, of which two are selectively vulnerable to nigrostriatal damage, while the third is more resistant.
Footnotes
-
This work was supported by the California Tobacco Related Disease Research Program Grants 7RT-0015 and 11RT-0216 and by National Institutes of Health Grants CA77349, MH53631, and DA12242.
-
DOI: 10.1124/jpet.102.039347
- Abbreviations:
- nAChR
- nicotinic acetylcholine receptor
- [125I]A-85380
- 5-[125I]iodo-3(2(S)-azetidinylmethoxy)pyridine
- MPTP
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- [125I]RTI-121
- 3β-(4-[125I]iodophenyl)tropane-2β-carboxylic acid isopropyl ester
- ∗
- nicotinic receptors containing the indicated α and/or β subunit and possibly also additional undefined subunits
- Received May 21, 2002.
- Accepted July 3, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|